Pharmacyclics, Inc. Release: IMBRUVICA Treatment Shows Efficacy And Tolerability In Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant /PRNewswire/ -- Pharmacyclics, Inc. today announced that treatment with IMBRUVICAA was associated with an 88% overall response rate , with a median time on study of 23.3 months, in 16 patients with relapsed/refractory high-risk chronic lymphocytic leukemia . These patients had a median of five prior therapies and 63% were high-risk del 17p CLL patients.
http://ift.tt/1vbTMjf
http://ift.tt/1vbTMjf
No comments:
Post a Comment